Markets
People interact at the Micron booth at the 3rd China...
People interact at the Micron booth at the Third China International Supply Chain Expo (Sheldon Cooper/Getty Images)

Wall Street analysts love Micron’s earnings. The market already loved them too much ahead of time.

A “sell the news” event.

Luke Kawa

Micron announced phenomenal fourth-quarter results: a top- and bottom-line beat along with guidance on earnings and profitability for the current quarter that exceeded every Wall Street analyst’s expectations.

And yet the stock is lower, even as the sell side largely sings the memory chip specialist’s praises.

In all, about a dozen analysts hiked their price target on Micron in the wake of these results.

“The company indicated its high bandwidth memory customer base has now increased to six customers and expects to sell out the remainder of its 2026 HBM supply within the next few months,” Needham & Co. analyst N. Quinn Bolton wrote, lifting his price target to $200 from $150 and maintaining a “buy” rating.

Bank of America kept its “neutral” rating on the shares, but lifted its price target to $180 from $140.

“Micron is benefitting from the dual-drivers of surging AI demand (driver of high bandwidth memory or HBM sales) and the memory industry’s (abnormal) supply discipline that has pushed up pricing in traditional (D4) and new (D5) markets,” analyst Vivek Arya wrote.

The problem seems to be that Wall Street has been in catch-up mode on the company, leading to a bit of a “sell the news” event.

On August 11, Micron told investors that the results it just reported would be better than management previously expected. And in September, the stock went on an absolute tear, with a record 12-session winning streak that pushed the price above the average target from the sell side. That move occurred amid a bevy of positive news on the persistence of the AI build-out, headlined by purchase commitments from OpenAI that range from $10 billion (with Broadcom) to the hundreds of billions (with Oracle). Micron’s memory chips are slated to play a supporting role in this continued aggressive development of AI infrastructure.

It’s much easier to say with hindsight that these fantastic results and outlook were priced in. But even a cursory look at the above chart would suggest that Micron needed to be an Olympic-level hurdler to clear the bar the market had set for this quarter.

“We made the case in our preview that even with excellent near term conditions, that the stock is nearing peak valuation if we treat them the way that we would historically treat a memory business,” wrote Morgan Stanley’s Joseph Moore, who kept his “neutral” rating and $160 price target intact following these results. “The stock is expensive on book value, extremely expensive on FCF metrics (which is our primary rationale for buying a memory stock), and is inexpensive on near term earnings, but expensive on cycle adjusted earnings.”

Even with today’s drop, shares of Micron are still up more than 30% this month.

More Markets

See all Markets
markets

Nike’s China business declines for seventh straight quarter

Sportswear kingpin Nike reported results for its third quarter, which ended in February, after the bell Tuesday. The stock fell about 3% in after-hours trading.

For fiscal Q3, Nike reported:

  • Earnings of $0.35 per share, comfortably above the Wall Street consensus of $0.29 per share compiled by FactSet.

  • $11.28 billion in total revenue, roughly in line with the $11.26 billion estimate.

Nike’s sales in China — where the company earns about 15% of its revenue — fell 7% to $1.62 billion. That’s its seventh straight quarter of sales declines in the market, though this quarter’s was less than feared. The company had issued weak guidance for this quarter considering continued softness in the region.

“This quarter we took meaningful actions to improve the health and quality of our business,” said Nike CEO Elliott Hill. “The pace of progress is different across the portfolio and the areas we prioritized first continue to drive momentum.”

Nike shares are trading near decade lows this month, as tariffs continue to weigh on profits and shipping costs rise amid the war with Iran. As of Tuesday’s close, the stock was down 17% year to date.

Oil-sensitive travel stocks pop following Iran state media reporting on potential war resolution

Travel stocks are surging on Tuesday as oil prices fall following reports from Iranian state media that President Masoud Pezeshkian said the country has the necessary will to end this war, but would only do so with guarantees that prevent the recurrence of aggression.

The war has sent oil prices and refining margins surging this month, causing airlines and cruise lines to cut profit forecasts despite reported high demand.

Following Tuesday’s update, shares of the big four US airlines (Delta Air Lines, United Airlines, American Airlines, and Southwest Airlines) all climbed, along with smaller rivals including JetBlue. US airlines have stopped fuel hedging in recent years, increasing their exposure to upward swings in oil prices.

Cruise stocks also rallied, with Carnival and Norwegian up more than 6% and Royal Caribbean up about 5%.

markets

The FDA is expected to lift restrictions on certain peptides, the NYT reports

The Food and Drug Administration is expected to lift restrictions on certain peptides, allowing the experimental, often injectable substances to be sold by compounding pharmacies, The New York Times reported Tuesday.

The potential move was previously reported by The Wall Street Journal, and teased by Health Secretary Robert F. Kennedy Jr. on the “Joe Rogan Experience” podcast in late February.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

Peptides have boomed in popularity recently, with search interest for “peptides” surpassing “ozempic” this month. Many of them are currently understudied and not approved for human use, a rule consumers are able to bypass by purchasing them from suppliers that sell them for, ostensibly, research purposes only.

As reports of the FDA changing its stance of peptides mount, consumer health companies like Hims & Hers and Superpower have been getting ready to roll out their peptide offerings as soon as they get the FDA's blessing.

markets

Memory stocks bounce as Bernstein analyst calls TurboQuant fears “overdone”

Memory stocks rose Tuesday, after Bernstein analysts called the recent panic over Google’s TurboQuant AI algorithm “overdone.”

Bernstein analyst Mark Newman wrote:

“[Hard disk drive] and Memory stocks have sold off significantly due in part to fears from Google’s TurboQuant report. This however, should have zero impact on HDD demand and negligible impact on NAND demand. Given the stock sell-off we see this as an attractive entry point for Seagate Technology Holdings, Western Digital and Sandisk’s and upgrade WDC to Outperform.”

All three stocks were up early Tuesday, as was memory chip maker Micron.

Todays rally stands in stark contrast to the pummeling these shares have endured over the last week, after Google Research published a technical paper on March 24 detailing its TurboQuant AI algorithm, which compresses the amount of data associated with AI operations without affecting the accuracy of AI models.

That was seen as a threat to surging AI demand for memory storage, which has supercharged prices for memory chips and memory-related stocks over the last year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.